Obesity: A dangerous condition linked to potentially serious metabolic health issues.
Obesity1, or excess body fat, is linked closely to metabolic syndrome, which impacts the body’s ability to regulate blood sugar, fats, and other important molecules. The presence of excess body fat increases the risk of type 2 diabetes, high blood pressure, high cholesterol, heart disease, and certain cancers. Controlling obesity is a critical component of maintaining healthy metabolic function and can reduce the risk of developing type 2 diabetes. Sustained weight maintenance is the key to ending obesity.
Limitations of current obesity drugs.
Lifelong therapy
Current drugs that treat obesity, like GLP-1s, often must be taken for the duration of a person’s life in order to maintain their effects.2
Side effects
People taking obesity drugs may experience undesirable side effects, like nausea, vomiting, and diarrhea.3
Rebound effect
Once obesity drugs are stopped, patients often experience rapid and excessive weight regain, as well as loss of the metabolic effects they had previously experienced (i.e. on blood sugar, cardiovascular risk factors, etc.)4
The role of the duodenum in obesity.
The duodenum, the first segment of the small intestine, is the first site of nutrient absorption in the body. A high-fat, high-sugar diet can damage the duodenum, changing its structure and function, and potentially cause obesity and type 2 diabetes.
Exploring new approaches to obesity.
Revita
An outpatient endoscopic procedure designed to resurface the nutrient sensing lining of the duodenum—targeting a root cause of obesity and type 2 diabetes.
Rejuva
A one-time gene therapy platform designed to enable long-term remission of obesity and type 2 diabetes by targeting pancreatic islet cells.
Now recruiting for a clinical research study in obesity.
- Obesity. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. The SURMOUNT-4 Randomized Clinical Trial. JAMA Network. https://jamanetwork.com/journals/jama/fullarticle/2812936
- Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994651/
- Wilding JPH, Diabetes Obes Metab.2022;24:1553–1564 (Funded by Novo Nordisk)
Revita® is for investigational use only in the US under Federal law. We hereby disclaim any warranties or guarantees regarding the efficacy or safety of Revita®. While we strive for quality and reliability, individual results may vary. Users are encouraged to consult with healthcare professionals and assess personal suitability before using the device.
Rejuva® is in early development and not approved by any regulatory body for investigational or commercial use.